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Abstract
Background—Whereas several longitudinal metabolomics studies have been conducted in 
individuals with normal eGFR at baseline, disease progression among individuals with established 
CKD has not been rigorously examined.
Methods—We performed a nested case-control study of rapid CKD progression in the Chronic 
Renal Insufficiency Cohort (CRIC) Study, profiling baseline plasma from 200 individuals each 
with eGFR slope < −3 ml/min/1.73m2/yr (cases) or between −1 and +1 ml/min/1.73m2/yr 
(controls), matched on baseline eGFR and proteinuria. To directly assess how the kidney 
modulates circulating metabolites, we profiled plasma from the aorta and renal vein of 25 hospital-
based individuals.
Results—At baseline, cases and controls had a mean eGFR of 41.7 ± 13.3 and 45.0 ± 14.5 
mL/min/1.73m2, respectively. Ten plasma metabolites were nominally associated with CKD 
progression in logistic regression models adjusted for age, sex, race/ethnicity, hypertension, 
systolic and diastolic blood pressure, diabetes, eGFR, and proteinuria; no metabolite achieved the 
Bonferroni-adjusted significance threshold (p<0.0003). In cross-sectional analysis, all six of the 
metabolites that were higher in cases than controls were significantly associated with eGFR at 
baseline. By contrast, threonine, methionine, and arginine were lower in cases than controls and 
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had no association with baseline eGFR. Further, in the hospital-based cohort that underwent renal 
arteriovenous sampling, these three metabolites were net released from the kidney. Combining 
these metabolites into a panel of markers further strengthened their association with CKD 
progression.
Conclusion—Our results motivate interest in arginine, methionine, and threonine as potential 
indicators of renal metabolic function and markers of renal prognosis.
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INTRODUCTION
Metabolomics, or metabolite profiling, refers to the systematic analysis of metabolites (i.e., 
sugars, amino acids, organic acids, nucleotides, etc) in a biologic specimen [1–3]. Because 
of long-standing interest in small molecules as potential uremic toxins, initial applications of 
metabolomics in nephrology research examined plasma or dialysate from individuals with 
ESRD [4–6]. At the other end of the spectrum of renal health, recent large scale profiling in 
population-based cohorts including the Framingham Heart Study (FHS), the Cooperative 
Health Research in the Region of Augsburg (KORA) Study, the TwinsUK Registry, and the 
Atherosclerosis Risk in Communities Study (ARIC) have identified cross-sectional 
associations between metabolite levels and eGFR within the normal range [7–10]. Because 
longitudinal follow-up is available in these cohorts, these data sets have also permitted 
assessment of the association of these baseline metabolite measures with the future onset of 
CKD.
Whereas studies of incident CKD have compared individuals who do or do not cross an 
eGFR threshold of 60 ml/min/1.73 m2, identifying markers of progression among 
individuals with established disease is arguably of greater interest. The relative paucity of 
high-quality cohorts enriched for advanced renal disease, however, presents a challenge. 
Here, we conducted a nested case-control study of disease progression in the Chronic Renal 
Insufficiency Cohort (CRIC) Study, a longitudinal, multi-center cohort study of individuals 
with CKD. Because of the possibility of confounding due to baseline difference in kidney 
function, we tested the cross-sectional association between the markers identified in the 
case-control analysis with baseline eGFR. In addition, in order to provide a physiologic 
understanding of how the kidneys modulate these potential metabolite markers, we analyzed 




The CRIC Study was initiated in 2001 by the NIDDK to investigate the natural history of 
kidney disease as well as the risk factors for disease progression and cardiovascular 
complications. Between 2003–2008, 3939 individuals with mild to moderate kidney disease 
were recruited at 13 sites across the US [11,12]. By design, approximately 50% of study 
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participants had diabetes at study entry when they were between the age of 21 and 74 years, 
with an eGFR of 20–70 ml/min/1.73 m2. The institutional review board of the Perelman 
School of Medicine at the University of Pennsylvania approved the study. The study adhered 
to the Declaration of Helsinki and all participants provided written informed consent.
Study Design
We used a nested case-control design, comparing a subset of the CRIC Study population 
demonstrating rapid progression of their renal disease (cases, n=200) to a subset whose renal 
dysfunction was stable over time (controls, n=200). Cases were randomly chosen from 
individuals with an eGFR slope < −3 ml/min/1.73 m2/yr. Controls were chosen from 
individuals with an eGFR slope between −1 and +1 ml/min/1.73 m2/yr. For each case, a 
control was selected that was in the same eGFR (<30, 30-<40, 40-<50, and ≥50 ml/min/1.73 
m2) and proteinuria (≤0.1, 0.1-<0.5, 0.5-<1.5, and ≥1.5 g/24h) category at study entry. eGFR 
was calculated from serum creatinine and cystatin C using a CRIC Study equation [13] and 
eGFR slope was derived using all available eGFR values using linear regression. Proteinuria 
was measured from 24h urine collections. Cardiovascular disease (CVD) and smoking status 
were self-reported whereas diabetes was defined as a fasting glucose ≥126 mg/dL, a random 
glucose ≥200 mg/dL, or use of insulin or antidiabetic medications. Systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) was measured in triplicate following a 
standardized protocol with the participant seated using a Tycos Classic hand cuff and 
aneroid sphygmomanometer (Welch Allyn, Skaneateles Falls, NY, USA). The baseline 
values were the mean of all three SBP and DBP measurements, separately. Hypertension 
was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg and/or self-reported 
antihypertensive medication use. Creatinine, glucose, and uric acid were measured using 
coupled enzymatic reactions with spectrophotometric quantification on the Ortho Vitros 950 
(Ortho Clinical Diagnostics, Raritan, NJ, USA). Metabolomics assays were performed on 
fasting plasma samples obtained at study entry and stored at −80°C.
Arterial and Renal Venous Plasma Sampling
Details on this protocol have been published [7]. In brief, we recruited consecutive patients 
referred to the Massachusetts General Hospital Cardiac Catheterization Laboratory for right 
and left heart catheterization. During the procedure, plasma was sampled from catheters 
placed in the ostium of a renal vein and the abdominal aorta. All patients were fasting and all 
samples were obtained prior to coronary artery catheterization (and administration of 
iodinated contrast dye). eGFR for study participants undergoing venous sampling was 
calculated using the MDRD equation [14]. The study protocol was approved by the 
institutional review board of the Massachusetts General Hospital, adhered to the Declaration 
of Helsinki, and all participants provided written informed consent.
Metabolite Profiling
Two liquid chromatography-mass spectrometry (LC-MS) methods were used to measure 
polar plasma metabolites. Amino acids, amino acid metabolites, acylcarnitines, dipeptides, 
nucleotides, and other cationic polar metabolites were measured in 10 μL of plasma using 
hydrophilic interaction liquid chromatography coupled with positive ion mode analysis on a 
Q Exactive Plus Orbitrap MS (Thermo Scientific, Waltham, MA, USA). Sugars, sugar 
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phosphates, organic acids, bile acids, nucleotides and other anionic polar metabolites were 
measured in 30 μL of plasma using hydrophilic interaction liquid chromatography and 
multiple reaction monitoring in the negative ion mode on a 5500 QTRAP MS (AB Sciex, 
Framingham, MA, USA). Details on plasma extraction, isotope internal standards, and 
chromatographic conditions for both methods have been published [4,15]. Metabolite 
identifications were confirmed using synthetic mixtures of reference compounds as well as 
characterized pooled plasma reference samples. All samples for a given study design (i.e. 
CRIC or renal arterio-venous sampling) were assayed in a single LC-MS run.
Statistical Analyses
We compared demographic and laboratory parameters between cases and controls using 
unpaired t-tests or Chi-squared tests, as appropriate. We compared select metabolites 
measured by LC-MS with spectrophotometric measurements using Pearson correlation 
coefficients. We compared medication levels between individuals with or without CVD and 
cotinine levels between non-smokers and smokers using the Wilcoxon rank-sum test. In the 
primary CRIC analysis, we fit logistic regression models to assess the associations between 
log transformed metabolite levels and rapid progression of CKD. The primary model 
adjusted for age, sex, race/ethnicity, hypertension, SBP, DBP, diabetes, eGFR and 
proteinuria; eGFR, and proteinuria were included as continuous variables. With 160 
endogenous metabolites measured in this cohort, the Bonferroni adjusted significance 
threshold was 0.0003. We considered a p-value <0.05 as nominally significant. In addition, 
we examined the cross-sectional association of log transformed metabolite levels with 
baseline eGFR in linear regression models adjusted for age, sex, race/ethnicity, hypertension, 
SBP, DPB, diabetes, and proteinuria, again with a Bonferroni adjusted significance threshold 
of p<0.0003. For the study of renal arteriovenous metabolite gradients, we compared arterial 
and venous metabolite levels using paired t-tests. Based on these initial analyses highlighting 
threonine, methionine, and arginine as potential markers of renal metabolic function 
independent of baseline GFR, data for these three metabolites were log transformed, 
standardized, and then summed to create a composite score. We hypothesized that this panel 
of metabolites provides a more complete assessment of renal metabolism and hence would 
have a stronger association with case status than any of the three metabolites alone. This 
panel of metabolites was examined in the primary model, as well as models further adjusting 
for CVD and smoking, and for CVD, smoking, hemoglobin, and FGF-23 levels. All analyses 
were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
CRIC Study
Baseline characteristics of the CRIC study sample are shown in Table 1. Rapid progressors 
(cases) were older (60.1 versus 57.8 years), more likely to be black (55% versus 35%), and 
had a higher prevalence of hypertension (95% versus 87%), diabetes (55% versus 44%), 
active smoking (20% versus 12%), and CVD (47% versus 36%) than individuals with stable 
kidney function (controls). Cases also had lower hemoglobin (12.7 versus 13.3 mg/dL) and 
higher FGF-23 (205.7 versus 159.4 RU/mL) levels, but there was no significant difference in 
bicarbonate, phosphate, cholesterol, insulin, or BMI. Although the groups were matched on 
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the basis of eGFR and proteinuria category, the mean eGFR at baseline was lower among 
cases compared to controls (41.7 ± 13.3 versus 45.0 ± 14.5 mL/min per 1.73 m2). There was 
no difference in proteinuria. The mean eGFR slope was −4.1 ± 1.0 and −0.1 ± 0.6 mL/min/
1.73 m2 per year among cases and controls, respectively. The mean follow-up was 2.84 +/
− 0.44 years, with no difference between cases and controls.
Metabolite Profiling in CRIC
A total of 160 polar metabolites were measured in baseline plasma obtained from cases and 
controls. First, we sought to examine this metabolite data in relation to several cross-
sectional phenotypes captured in CRIC (Figure 1). Figure 1A depicts the correlation for 
three metabolites assayed by our LC-MS methods that had already been measured in CRIC 
using alternative (spectrophotometric) methods. The Pearson correlation coefficients were 
0.86 for creatinine, 0.81 for glucose, and 0.54 for uric acid. Figure 1B shows data on select 
medications (or medication metabolite) monitored by our platform. Individuals with self-
reported CVD had higher plasma levels of metoprolol, carvedilol, lisinopril, warfarin, and 
salicylurate (a metabolite of aspirin) than individuals without CVD. Finally, Figure 1C 
shows plasma levels of the nicotine metabolite cotinine in non-smokers versus smokers, 
demonstrating markedly elevated mean levels in the latter group, albeit with notable overlap 
in the distributions.
Metabolite Associations with Rapid CKD Progression
Endogenous metabolites with a nominal association (p < 0.05) with CKD progression in 
logistic regression, adjusted for age, sex, race/ethnicity, hypertension, SBP, DBP, diabetes, 
baseline eGFR and proteinuria, are shown in Table 2 (full results are shown in 
Supplementary data, Table S1). No metabolite met the Bonferroni-adjusted threshold for 
significance. Of the ten metabolites nominally associated with CKD progression, six (uric 
acid, glucuronate, 4-hydroxymandelate, 3-methyladipate/pimelate, cytosine, and 
homogentisate) were higher in cases than controls, whereas four (threonine, methionine, 
phenylalanine, and arginine) were lower in cases than controls. Because many circulating 
small molecules (including metabolites) accumulate with falling GFR, we also examined the 
cross-sectional association between metabolite levels and baseline eGFR in linear regression 
models adjusted for age, sex, race/ethnicity, hypertension, SBP, DBP, diabetes, and 
proteinuria. Notably, all six of the metabolites that were higher in cases than controls had a 
significant (p<0.0003) association with baseline eGFR, with an inverse correlation between 
metabolite level and eGFR (Table 2). These findings raise the possibility that the association 
between these metabolites and subsequent GFR decline is confounded by baseline 
differences in renal function not fully captured by one-time GFR estimation. By contrast, 
threonine, methionine and arginine – three metabolites that were lower in cases than controls 
– had no association with eGFR at baseline (Table 2).
Renal Arterio-Venous Metabolite Gradients
We have previously reported metabolomics data on a pilot study of nine individuals who 
underwent aortic and renal venous sampling, thus providing an initial view of how 
metabolites are modulated at the organ level [7]. Here, we present data from the complete set 
of 25 individuals enrolled in the protocol. Clinical characteristics of this hospital-based 
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cohort are shown in Supplementary data, Table S2. Two individuals had ESRD and were on 
hemodialysis. The remaining 23 individuals had a mean eGFR of 68.1 ± 19.2 mL/min/1.73 
m2. Whereas creatinine levels did not change from aorta to renal vein in the two individuals 
with ESRD, they fell in all the others. Figure 2 shows the ratio of renal venous to arterial 
creatinine in each individual. As expected, the decrement in creatinine was lower in 
individuals with lower eGFR (and negligible in the two individuals with ESRD). The mean 
venous to arterial ratio (V/A) for creatinine was 0.81. Table 3 shows the mean V/A for the 
metabolites with nominal associations with CKD progression in CRIC (full results are 
shown in Supplementary data, Table S3). Of these ten metabolites, seven had a V/A ratio ≤1. 
By contrast, three metabolites had a mean V/A >1, indicating net renal release of these 
metabolites. Notably, in CRIC all three of the metabolites – threonine, methionine, and 
arginine – were lower at baseline among individuals with rapid CKD progression compared 
to individuals with stable CKD and had no association with baseline eGFR.
A Panel of Markers of Renal Metabolic Function
Next, we created a panel of markers comprised of the three metabolites with V/A ratio >1 
highlighted by our invasive catheterization studies above. The association between this panel 
of markers and eGFR decline in CRIC is shown in Table 4. In the logistic regression model 
adjusted for age, sex, race/ethnicity, hypertension, SBP, DBP, diabetes, eGFR and 
proteinuria (Model 1), the panel of markers had an OR of 0.87 (0.79–0.96) per SD (P = 
0.004). Individuals in the second tertile had an OR of 0.81 (0.48–1.37) and individuals in the 
third tertile had an OR of 0.44 (0.26–0.76) compared to individuals in the first tertile of the 
marker panel (P = 0.003 for trend). Results were unchanged when the model was further 
adjusted for CVD and smoking status at baseline (Model 2) or CVD, smoking status, 
hemoglobin, and FGF-23 levels (Model 3).
DISCUSSION
Current blood markers of CKD, i.e. serum creatinine and blood urea nitrogen, are unable to 
identify which individuals will progress and do not provide insight on underlying causal 
pathways. Increasing interest in CKD biomarker research has been directed towards 
metabolomics-based discovery because of the broad impact kidney function has on 
circulating metabolites and because metabolites may themselves play functional roles in 
CKD pathogenesis. In a nested case-control analysis in the CRIC Study, we found several 
metabolite alterations nominally associated with subsequent disease progression. Although 
these metabolite associations were not significant after adjusting for multiple testing, our 
data on renal arteriovenous gradients coupled with an analysis of cross-sectional metabolite 
associations with eGFR nominate select markers of renal metabolic function for future 
investigation.
In order to illustrate the value of metabolite profiling in the context of a well characterized 
clinical cohort, we examined metabolite measures in relation to several phenotypes 
ascertained in CRIC. For metabolites that had been assayed previously, the correlation with 
our LC-MS measures ranged from excellent (creatinine) to modest (uric acid). Given the 
multiplex nature of the LC-MS methods, it is possible that the individualized measures 
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provide more precise results. However, we do note that our LC-MS data were generated in a 
single sample run, thus circumventing any issues with batch effect or inter-laboratory 
variability that may have affected the spectrophotometric data. In this regard, it is interesting 
that the association between uric acid and CKD progression is stronger for data generated by 
LC-MS (OR 9.72 [2.17–43.45], P = 0.003) than enzymatic assay (OR 2.13 [0.80–5.69], P = 
0.13, not shown). In other studies, uric acid has been found to have a variable association 
with incident CKD and CKD progression, and whether it is a modifiable risk factors remains 
an area of controversy [16–20]. In addition to overlap with previously examined endogenous 
metabolites, our platform provides an objective read-out of medication and nicotine input; in 
the case of smoking our data indicate that some self-reported non-smokers are in fact subject 
to considerable nicotine exposure, either directly or as a result of second-hand smoke. By 
integrating both endogenous and exogenous (i.e. pharmaceutical or environmental) inputs, 
metabolomics has the potential to more finely subtype study participants and risk factors in 
epidemiologic studies.
Our primary analysis, a case-control examination of metabolites and CKD progression in 
CRIC, builds on and extends a growing body of literature. Several large studies have 
examined baseline metabolite levels in >1000 subjects each from FHS, KORA, TwinsUK, 
and ARIC in relation to the subsequent development of CKD, i.e. crossing below an eGFR 
of 60 mL/min/1.73m2 [7–10]. Niewczas et al. examined 80 individuals with diabetic 
nephropathy at the Joslin Diabetes Center, 40 of whom progressed to ESRD [21]. 
Acknowledging that incomplete overlap of platform coverage significantly limits 
comparison across studies, no dominant signal has emerged. In general, however, each of 
these prior studies have identified robust statistical associations between select metabolites 
and eGFR decline even after adjusting for multiple testing. Two major differences in our 
study warrant mention. First, unlike the prior studies we matched cases and controls on 
baseline eGFR and proteinuria. Second, we examined individuals starting at a much lower 
mean eGFR. The studies cited above had mean eGFRs of 93.6 (FHS), 81.0 (KORA), 93.8 
(Twins UK), 105.3 (ARIC), and 81.0 mL/min/1.73 m2 (Joslin), whereas individuals in our 
study started with a mean eGFR of 43.3 mL/min/1.73 m2. It is possible that as kidney 
function declines, nonspecific accumulation dilutes the risk signal attributable to select 
metabolite alterations, particularly metabolite elevations.
In addition to filtering and secreting many plasma metabolites, the kidneys are also 
responsible for the net release of some metabolites back into circulation. For example, prior 
studies have firmly established the kidney as an important source of circulating arginine via 
the intra-renal transamination of citrulline to arginine [22,23]. Our data in CRIC raise the 
possibility that impairment of this metabolic function is associated with subsequent CKD 
progression. Interestingly, we found that two additional amino acids nominally associated 
with CKD progression in CRIC were both depleted in cases relative to controls and were net 
released across the kidney. None of these three metabolites were correlated with baseline 
eGFR, and a panel of markers comprised of all three metabolites had a stronger association 
with case status than each individual analyte. Thus, we raise the hypothesis that arginine, 
methionine, and threonine are markers of renal metabolic function and that at advanced 
stages of renal dysfunction their plasma levels provide insight on renal prognosis. Consistent 
with this paradigm, we note that other read-outs of known renal anabolic functions, i.e. 
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hemoglobin (from erythropoietin) and 1,25-hydroxyvitamin D levels are associated with 
renal disease progression [24–27]. In addition to reporting on renal metabolic capacity, we 
do not rule out the possibility that select metabolite depletions could play a causal role in 
disease progression; for example, as the substrate for nitric oxide synthase, limited arginine 
bioavailability could have deleterious vascular effects pertinent to CKD progression.
Our study has several strengths. First, it is the largest metabolomics study to date of disease 
progression in established CKD, utilizing high quality samples from a well-phenotyped, 
racially diverse cohort. Second, our LC-MS based platform has an established record in 
biomarker studies of ESRD, diabetes, and cancer as well as genome-wide association study, 
generating robust associations that in many cases have been confirmed by other investigators 
[4,15,28–31]. Third, to our knowledge the summary of renal arteriovenous metabolite 
gradients we have generated is a unique data set and is provided in full in the Supplement. 
We believe this will be a valuable resource for the interpretation of metabolomics biomarker 
studies, in nephrology and beyond.
Our study also has several limitations. Most important is the lack of a replication cohort. 
Clearly, follow-up studies are required to substantiate the metabolite signals identified in our 
analysis, including the panel of markers of renal metabolic function. Although the 
construction of this panel was informed by physiologic data, we acknowledge that 
combining markers significantly increases the potential number of comparisons, 
necessitating rigorous validation. Our focus on plasma is an additional limitation. Recently, 
Sharma et al. found decreased levels of several metabolites linked to mitochondrial 
metabolism in the urine of individuals with diabetic kidney disease [32]. We focused 
initially on plasma to build on our prior plasma based studies of incident CKD and ESRD 
and in order to integrate our results with our data on arteriovenous gradients. Future studies 
should clearly test urine metabolites as markers of CKD progression as well. Future studies 
should also investigate a wider breadth of metabolites. Whereas we utilized a targeted 
approach to measure a subset of the metabolome, methods capable of measuring thousands 
of metabolite peaks (many of unknown identity) are being increasingly deployed in 
biomarker research.
In conclusion, metabolite profiling in a nested case-control study in the CRIC Study 
revealed modest metabolite associations with CKD progression. The major difference with 
prior renal metabolomics studies demonstrating stronger statistical associations with eGFR 
decline is the considerably lower starting eGFR in our study, which likely results in the 
nonspecific accumulation of many solutes. In conjunction with an examination of renal 
arteriovenous gradients our data nevertheless generate interest in metabolite depletion as a 
potential indicator of renal health. Future efforts will be directed at replicating these 
observations, as well as expanding the scope of metabolites measured, in a larger sampling 
of the CRIC Study. These efforts will also investigate whether metabolite profiling can 
supplement or even clarify other variables captured in CRIC including other biomarkers, 
medication adherence and comorbidities, and differences in dietary habits and the 
microbiome.
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Figure 1. Examination of select metabolomics data in relation to CRIC phenotyping
(a) Correlation between LC-MS (y-axis) and spectrophotometric measures (x-axis) of 
creatinine, glucose, and uric acid. (b) Mean medication levels in individuals with (n=166) or 
without (n=234) self-reported CVD at baseline. Bars represent SEM. *p < 0.05, #p < 0.001. 
(c) Distribution of plasma cotinine levels in self-reported non-smokers and smokers; note y-
axis is log scale.
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Figure 2. Renal venous to arterial creatinine ratio in 25 individuals
Each data point represents one individual, with eGFR (estimated by MDRD) plotted on the 
x-axis and creatinine V/A ratio plotted on the y-axis. The two triangles represent the 2 study 
subjects with ESRD.
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Table 1
Baseline characteristics of the CRIC Study sample
Rapid progressors (cases) Stable CKD (controls) p-value
Clinical characteristics
Age (years) 60.1 ± 10.2 57.8 ± 11.3 0.04
Male sex (%) 57 64
Race/ethnicity
white 31% white 51%
black 55% black 35% <0.001
other 14% other 14%
Hypertension (%) 95 87 0.004
Systolic blood pressure (mmHg) 134.5 ± 21.4 121.9 ± 20.0 <0.001
Diastolic blood pressure (mmHg) 72.1 ± 13.8 70.1 ± 12.7 0.14
Body mass index (kg/m2) 32.5 ± 7.8 32.1 ± 7.1 0.53
Diabetes (%) 55 44 0.03
Cardiovascular disease (%) 47 36 0.04
Smokers (%) 20 12 0.03
Laboratory measures
Serum creatinine (mg/dL) 1.86 ± 0.6 1.82 ± 0.6 0.58
Baseline eGFR (mL/min/1.73 m2)† 41.7 ± 13.3 45.0 ± 14.5 0.02
Follow-up eGFR (mL/min/1.73 m2) 24.7 ± 10.5 45.0 ± 11.2 <0.001
24h urine protein (g) 0.9 ± 1.6 0.8 ± 1.3 0.27
Hemoglobin (mg/dL) 12.7 ± 1.7 13.3 ± 1.9 0.002
Bicarbonate (mmol/L) 24.3 ± 3.4 24.7 ± 2.9 0.12
Phosphate (mg/dL) 3.7 ± 0.7 3.6 ± 0.6 0.05
FGF-23 (RU/mL) 205.7 ± 249.1 159.4 ± 137.0 0.02
Insulin (μIU/mL) 25.7 ± 25.6 26.8 ± 33.4 0.73
Total cholesterol (mg/dL) 177.2 ± 44.3 176.1 ± 38.4 0.78
HDL cholesterol (mg/dL) 47.7 ± 13.0 48.6 ± 15.7 0.55
LDL cholesterol (mg/dL) 95.2 ± 34.4 94.7 ± 29.8 0.89
Triglycerides (mg/dL) 158.2 ± 112.7 154.0 ± 96.6 0.66
†
baseline eGFR using the CKD-EPI equation was 43.9 ± 13.9 for cases and 44.6 ± 13.4 mL/min/1.73 m2 for controls
Conversion factor for units: serum creatinine in mg/dL to mmol/L, x88.4
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Table 3
Renal arteriovenous gradients for metabolites nominally associated with rapid CKD progression in CRIC
Metabolite # of individuals with V/A <1 # of individuals with V/A ≥1 Mean V/A Ratio p-value
homogentisate* 22 0 0.37 <0.001
4-hydroxymandelate* 22 0 0.37 <0.001
3-methyladipate-pimelate 23 0 0.60 <0.001
cytosine 21 2 0.80 <0.001
glucuronate 23 0 0.85 <0.001
uric acid 20 3 0.98 0.02
phenylalanine 10 13 1.00 0.9
threonine 3 20 1.07 <0.001
methionine 2 21 1.10 <0.001
arginine 0 23 1.16 <0.001
creatinine 23 0 0.81 <0.001
Abbreviation: V/A = venous to arterial ratio
*
no data on these metabolites for one study participant
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